Noncoding RNA control of neuroinflammation in Alzheimer’s disease: from immune cell states to precision therapeutics
4 affiliations
- 1Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine (The Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine)
- 2Hunan University of Chinese Medicine
- 3The First Hospital of Hunan University of Chinese Medicine
- 4Mucosal Immunology Section, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH)
Abstract
Neuroinflammation is an active and heterogeneous component of Alzheimer’s disease, shaped by dynamic interactions among microglia, astrocytes, neurons, and brain-interface compartments. Noncoding RNAs, including microRNAs, long noncoding RNAs, circular RNAs, and emerging small-RNA species, regulate innate immune sensing, interferon responses, phagocytosis, metabolic adaptation, inflammasome activity, and neuronal stress. Their effects are strongly context dependent: the same noncoding RNA can exert different or even opposing functions according to cell identity, intracellular or extracellular localization, disease stage, and dose. Extracellular vesicles and extracellular RNA sensing further extend noncoding RNA activity beyond cell-autonomous regulation, creating intercellular circuits that couple neuronal stress to glial immune states. Noncoding RNA-regulated inflammation intersects with amyloid-β production and clearance, tau-associated stress, synaptic dysfunction, mitochondrial impairment, and regulated cell death. Rather than acting as isolated inflammatory switches, noncoding RNAs appear to tune the strength of pathological feedback networks that determine whether proteotoxic and inflammatory stress is contained or progressively amplified. The translational value of individual noncoding RNAs depends on the convergence of causal evidence, mechanistic resolution, human relevance, and therapeutic tractability. Human brain, cerebrospinal fluid, patient-derived extracellular vesicles, and induced pluripotent stem cell models are beginning to bridge experimental mechanism and human disease, while antisense oligonucleotides, engineered extracellular vesicles, targeted nanoparticles, and synthetic circular RNAs provide emerging therapeutic routes. Pleiotropy, cell-type specificity, disease-stage dependence, endosomal trafficking, and innate RNA sensing remain major barriers. Context-resolved noncoding RNA regulatory nodes that control defined neuroimmune states may ultimately enable precision neuroimmune reprogramming while preserving protective immune functions.
Related
- Mechanistic insights of Artemisia-derived therapeutics in Alzheimer’s disease (AD): from crude botanical extracts to artemisinin and derivatives
- The evolving landscape of fungal keratitis: from emerging pathogens to precision diagnostics and novel therapeutics
- AI-driven multi-omics biomarkers in precision breast cancer therapeutics: from discovery to clinical translation
- Advancing Therapeutics for Children with Medical Complexity: The Role of Model‐Informed Precision Dosing and Genotype‐Stratified Trials
- Alzheimer's Disease Neurofibrillary Pathophysiology: PTPRD- and Flavonol-Modified Mechanisms, Prevention and Therapeutics.
BibTeX
@article{zhou2026noncoding,
title = {{Noncoding RNA control of neuroinflammation in Alzheimer’s disease: from immune cell states to precision therapeutics}},
author = {Shengqiang Zhou and Yanjun Chen and Xiping Yang and Liqin Xiang and Bo Li and Lingling Qiu and Zhuo Liu and Tiantian Zhang and Fang Liu and Liuting Zeng and Guo Mao},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1998588},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1998588/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Noncoding RNA control of neuroinflammation in Alzheimer’s disease: from immune cell states to precision therapeutics
AU - Shengqiang Zhou
AU - Yanjun Chen
AU - Xiping Yang
AU - Liqin Xiang
AU - Bo Li
AU - Lingling Qiu
AU - Zhuo Liu
AU - Tiantian Zhang
AU - Fang Liu
AU - Liuting Zeng
AU - Guo Mao
PY - 2026
DA - 2026/10/28
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1998588
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1998588/full
AB - Neuroinflammation is an active and heterogeneous component of Alzheimer’s disease, shaped by dynamic interactions among microglia, astrocytes, neurons, and brain-interface compartments. Noncoding RNAs, including microRNAs, long noncoding RNAs, circular RNAs, and emerging small-RNA species, regulate innate immune sensing, interferon responses, phagocytosis, metabolic adaptation, inflammasome activity, and neuronal stress. Their effects are strongly context dependent: the same noncoding RNA can exert different or even opposing functions according to cell identity, intracellular or extracellular localization, disease stage, and dose. Extracellular vesicles and extracellular RNA sensing further extend noncoding RNA activity beyond cell-autonomous regulation, creating intercellular circuits that couple neuronal stress to glial immune states. Noncoding RNA-regulated inflammation intersects with amyloid-β production and clearance, tau-associated stress, synaptic dysfunction, mitochondrial impairment, and regulated cell death. Rather than acting as isolated inflammatory switches, noncoding RNAs appear to tune the strength of pathological feedback networks that determine whether proteotoxic and inflammatory stress is contained or progressively amplified. The translational value of individual noncoding RNAs depends on the convergence of causal evidence, mechanistic resolution, human relevance, and therapeutic tractability. Human brain, cerebrospinal fluid, patient-derived extracellular vesicles, and induced pluripotent stem cell models are beginning to bridge experimental mechanism and human disease, while antisense oligonucleotides, engineered extracellular vesicles, targeted nanoparticles, and synthetic circular RNAs provide emerging therapeutic routes. Pleiotropy, cell-type specificity, disease-stage dependence, endosomal trafficking, and innate RNA sensing remain major barriers. Context-resolved noncoding RNA regulatory nodes that control defined neuroimmune states may ultimately enable precision neuroimmune reprogramming while preserving protective immune functions.
SN - 1664-3224
ER -